Although the prognostic implications of residual mutations in AML patients post‐induction in genes other than DNMT3A, ASXL1, and TET2 have previously been demonstrated,[3] there have been relatively few studies that have examined the significance of NGS‐defined residual disease in the pre‐stem cell transplant setting. This evidence concerns the gene ASXL1 and acute myeloid leukemia.